Observational studyClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Time-Anchored miR-424-5p Predicts Neurological Deterioration and 90-Day Disability After Acute Ischemic Stroke.
Observational study in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundCirculating microRNAs may predict stroke outcomes, but unaccounted sampling time can distort their prognostic value. We assessed whether plasma miR-424-5p interpreted with the elapsed time from stroke onset to blood draw predicted early neurological deterioration (END) and 90-day disability after acute ischemic stroke.MethodsThis prospective single-center observational cohort enrolled consecutive adults with imaging-confirmed acute ischemic stroke in China from June 2024 to June 2025. Time zero was the first research plasma draw with contemporaneous baseline NIHSS assessment. Primary analyses evaluated post-baseline END within 72 hours and 90-day disability in patients with valid repeat sampling 18-30 hours after time zero. Baseline miR-424-5p and 24-hour change normalized to the actual interval between the two blood draws were tested using multivariable models adjusted for pretreatment/time-zero covariates and onset-to-draw windows, with bootstrap internal validation.ResultsAmong 368 patients, 73 developed END (19.8%). The repeat-sample cohort included 337 patients, of whom 149 had 90-day disability (44.2%). Higher baseline miR-424-5p independently predicted END (adjusted OR per 1 SD, 1.57; 95% CI, 1.16-2.13; p=0.003). For 90-day disability, normalized 24-hour miR-424-5p change, but not baseline level, remained independently associated with outcome (adjusted OR per 1 SD, 1.69; 95% CI, 1.24-2.31; p=0.001). Within this development dataset, biomarker addition yielded apparent AUC changes from 0.79 to 0.83 for END and from 0.80 to 0.84 for disability.ConclusionsTime-anchored baseline miR-424-5p predicted post-baseline END, whereas its normalized 24-hour trajectory predicted 90-day disability. External validation, including comparison with 24-hour neurological reassessment, is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.